Chinese Clinical Oncology

• 综述与讲座 • Previous Articles     Next Articles

CTLA-4 monoclonal antibodytargeted passive immunotherapy for tumor

ZHOU Yan,DONG Wen,MA Jin'an.   

  1. Department of Oncology,the Second Xiangya Hospital of Central South University,Changsha 410011,China
  • Received:2012-10-29 Revised:2012-12-11 Online:2013-03-31 Published:2013-03-31

Abstract: Cellular immune system plays a very important role in the body's immune response to malignant tumor. Cytotoxic T lymphocyteassociated antigen 4(CTLA-4) involves in the induction and maintenance of T cell immune tolerance through inhibiting T cell activity,so the monoclonal antibody which blocks the CTLA-4 can stimulate the proliferation of immune cells,thereby enhances the body's immune response to the tumor. This paper mainly reviews the research progresses about CTLA-4 monoclonal antibody drugs(ipilimumab and tremelimumab) in recent years and the clinical application progress of them.

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!